Targeting the Renin Angiotensin System in Dialysis Patients

Seminars in Dialysis

Volumn 24, Issue 3, 2011, Pages 290-297

  Cravedi, Paolo ^a   Remuzzi, Giuseppe ^a   Ruggenenti, Piero ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; KIDNEY FAILURE; METABOLISM; MORTALITY; PERITONEAL FIBROSIS; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL FIBROSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM;

EID: 79959362380     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00939.x     Document Type: Review

References (91)

1. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9:1136-1142, 1994
2. Gupta R, Birnbaum Y, Uretsky BF: The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol 44:1343-1353, 2004
3. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137:563-570, 2002
4. Lopez-Gomez JM, Verde E, Perez-Garcia R: Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Kidney Int Suppl 68:S92-S98, 1998
5. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, Mcmahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395-1407, 2009
6. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248, 2005
7. The Sharp Collaborative group: Should we reduce LDL cholesterol in patients with chronic kidney disease? the results of the study of heart and renal protection (SHARP). Abstract at the American Society Nephrology Meeting, 2010
8. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359:1343-1356, 2008
9. Ruggenenti P, Cravedi P, Remuzzi G: The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 6:319-330, 2010
10. Remuzzi G, Ruggenenti P: Overview of randomised trials of ACE inhibitors. Lancet 368:555-556, 2006
11. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355:1575-1581, 2000
12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
13. Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782-788, 2003
14. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351:2058-2068, 2004
15. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD: Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 47:1576-1583, 2006
16. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368:581-588, 2006
17. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134:629-636, 2001
18. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moye LA, Pfeffer MA, Solomon SD: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 110:3667-3673, 2004
19. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42:201-208, 2003
20. Mccullough PA, Sandberg KR, Yee J, Hudson MP: Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst 3:188-191, 2002
21. Anavekar NS, Mcmurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285-1295, 2004
22. Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P: Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70:1318-1324, 2006
23. Tai DJ, Lim TW, James MT, Manns BJ, Tonelli M, Hemmelgarn BR: Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 5:623-630, 2010
24. Stack AG, Bloembergen WE: A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 38:992-1000, 2001
25. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890, 1995
26. K/DOQI Workgroup: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45:S1-S153, 2005
27. Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 153:1064-1073, 2007
28. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2002
29. Cice G, Di Benedetto A, D'isa S, D'andrea A, Marcelli D, Gatti E, Calabro R: Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 56:1701-1708, 2010
30. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
31. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 49:1428-1434, 1996
32. Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S: Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol 8:1764-1770, 1997
33. Wang AY, Li PK, Lui SF, Sanderson JE: Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence? Nephrology (Carlton) 9:190-197, 2004
34. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003, 2002
35. Ruggenenti P, Iliev I, Costa GM, Parvanova A, Perna A, Giuliano GA, Motterlini N, Ene-Iordache B, Remuzzi G: Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 31:1629-1634, 2008
36. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30:659-664, 1997
37. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
38. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370-2375, 2001
39. Flegel KM, Hutchinson TA, Mulsant BH, Kramer MS: Adverse reactions to antihypertensive drugs. JAMA 257:1329-1330, 1987
40. Genovesi S, Pogliani D, Faini A, Valsecchi MG, Riva A, Stefani F, Acquistapace I, Stella A, Bonforte G, Devecchi A, Decristofaro V, Buccianti G, Vincenti A: Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 46:897-902, 2005
41. Benjamin EJ, Wolf PA, D'agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98:946-952, 1998
42. Winkelmayer W, Patrick A, Liu J, Brookhart M, Setoguch S: The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22(2):349-357, 2011
43. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, Dhein S: Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 42:1785-1792, 2003
44. Goette A, Ittenson A, Hoffmanns P, Reek S, Hartung W, Klein H, Ansorge S, Geller JC: Increased expression of P-selectin in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol 23:1872-1875, 2000
45. Doronin SV, Potapova IA, Lu Z, Cohen IS: Angiotensin receptor type 1 forms a complex with the transient outward potassium channel Kv4.3 and regulates its gating properties and intracellular localization. J Biol Chem 279:48231-48237, 2004
46. Chen YJ, Chen YC, Tai CT, Yeh HI, Lin CI, Chen SA: Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. Br J Pharmacol 147:12-22, 2006
47. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 101:2612-2617, 2000
48. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608-2614, 2001
49. Shi Y, Li D, Tardif JC, Nattel S: Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 54:456-461, 2002
50. Boldt A, Scholl A, Garbade J, Resetar ME, Mohr FW, Gummert JF, Dhein S: ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 101:261-267, 2006
51. Von Lewinski D, Kockskamper J, Rubertus SU, Zhu D, Schmitto JD, Schondube FA, Hasenfuss G, Pieske B: Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur J Heart Fail 10:1172-1176, 2008
52. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE: Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55:2299-2307, 2010
53. Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, Valsecchi MG: Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51:255-262, 2008
54. Brener ZZ, Thijssen S, Kotanko P, Kuhlmann MK, Bergman M, Winchester JF, Levin NW: The impact of residual renal function on hospitalization and mortality in incident hemodialysis patients. Blood Purif 31:243-251, 2011
55. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 41:1293-1302, 2003
56. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
57. Ruggenenti P, Perna A, Remuzzi G: ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12:2832-2837, 2001
58. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11:556-564, 2000
59. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139:105-112, 2003
60. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H: Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 43:1056-1064, 2004
61. Fang W, Oreopoulos DG, Bargman JM: Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 23:3704-3710, 2008
62. National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47:S1-S145, 2006
63. van de Ven PJ, Beutler JJ, Kaatee R, Beek FJ, Mali WP, Koomans HA: Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 53:986-993, 1998
64. Devoy MA, Tomson CR, Edmunds ME, Feehally J, Walls J: Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 232:493-498, 1992
65. Schild AF: Maintaining vascular access: the management of hemodialysis arteriovenous grafts. J Vasc Access 11:92-99, 2010
66. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC: Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 80:1726-1736, 1989
67. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59:2325-2334, 2001
68. Hehrlein C: How do AV fistulae lose function? The roles of haemodynamics, vascular remodelling, and intimal hyperplasia Nephrol Dial Transplant 10:1287-1290, 1995
69. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438, 1994
70. Nakamura Y, Nakamura K, Matsukura T, Nakamura K: Vascular angiotensin converting enzyme activity in spontaneously hypertensive rats and its inhibition with cilazapril. J Hypertens 6:105-110, 1988
71. Sajgure A, Choudhury A, Ahmed Z, Choudhury D: Angiotensin converting enzyme inhibitors maintain polytetrafluroethylene graft patency. Nephrol Dial Transplant 22:1390-1398, 2007
72. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW: Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40:1255-1263, 2002
73. Diskin CJ, Stokes TJ, Thomas SG, Ravis W, Lock S, Thomas J, Panus LW, Dansby L, Carter T: An analysis of the effect of routine medications on hemodialysis vascular access survival. Nephron 78:365-368, 1998
74. Marchesi C, Paradis P, Schiffrin EL: Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29:367-374, 2008
75. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB: Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 25:38-47, 2005
76. Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, Akcicek F, Atabay G: Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 21:219-224, 2001
77. Kolesnyk I, Dekker FW, Noordzij M, Le Cessie S, Struijk DG, Krediet RT: Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 27:446-453, 2007
78. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT: A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 24:272-277, 2009
79. Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD: Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112:110-114, 2002
80. Agarwal R, Afzalpurkar R, Fordtran JS: Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 107:548-571, 1994
81. Gross E, Rothstein M, Dombek S, Juknis HI: Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 46:94-101, 2005
82. Michea L, Vukusich A, Gonzalez M, Zehnder C, Marusic ET: Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int 66:1647-1653, 2004
83. Tielemans C, Madhoun P, Lenaers M, Schandene L, Goldman M, Vanherweghem JL: Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 38:982-984, 1990
84. Parnes EL, Shapiro WB: Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 40:1148-1152, 1991
85. Akizawa T, Kinugasa E, Wakasa M, Kohjiro S, Koiwa F, Koshikawa S: Effect of dialysis membranes and ACE inhibitor on bradykinin levels during hemodialysis. Clin Nephrol 41:241-244, 1994
86. Verresen L, Fink E, Lemke HD, Vanrenterghem Y: Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 45:1497-1503, 1994
87. Nadir MA, Szwejkowski BR, Witham MD: Vitamin D and cardiovascular prevention. Cardiovasc Ther 28:e5-e12, 2010
88. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, Kong J, Shi H, Chang A, Li YC: Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 77:1000-1009, 2010
89. Valdivielso JM, Cannata-Andia J, Coll B, Fernandez E: A new role for vitamin D receptor activation in chronic kidney disease. Am J Physiol Renal Physiol 297:F1502-F1509, 2009
90. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543-1551, 2010
91. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A: Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 37:407-411, 2001